Environment, Endocrine Disruptors, and Fatty Liver Disease Associated with Metabolic Dysfunction (MASLD)
- PMID: 38276306
- PMCID: PMC10819942
- DOI: 10.3390/metabo14010071
Environment, Endocrine Disruptors, and Fatty Liver Disease Associated with Metabolic Dysfunction (MASLD)
Abstract
Ecological theories suggest that environmental factors significantly influence obesity risk and related syndemic morbidities, including metabolically abnormal obesity associated with nonalcoholic fatty liver disease (MASLD). These factors encompass anthropogenic influences and endocrine-disrupting chemicals (EDCs), synergistically interacting to induce metabolic discrepancies, notably in early life, and disrupt metabolic processes in adulthood. This review focuses on endocrine disruptors affecting a child's MASLD risk, independent of their role as obesogens and thus regardless of their impact on adipogenesis. The liver plays a pivotal role in metabolic and detoxification processes, where various lipophilic endocrine-disrupting molecules accumulate in fatty liver parenchyma, exacerbating inflammation and functioning as new anthropogenics that perpetuate chronic low-grade inflammation, especially insulin resistance, crucial in the pathogenesis of MASLD.
Keywords: EDCs; MASLD; children; insulin-resistance.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
The Interplay between Endocrine-Disrupting Chemicals and the Epigenome towards Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review.Nutrients. 2024 Apr 11;16(8):1124. doi: 10.3390/nu16081124. Nutrients. 2024. PMID: 38674815 Free PMC article. Review.
-
The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease.Curr Mol Med. 2012 Jan;12(1):68-82. doi: 10.2174/156652412798376161. Curr Mol Med. 2012. PMID: 22082482 Review.
-
Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.Biomedicines. 2023 Oct 12;11(10):2761. doi: 10.3390/biomedicines11102761. Biomedicines. 2023. PMID: 37893134 Free PMC article. Review.
-
Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.Cureus. 2023 Oct 17;15(10):e47240. doi: 10.7759/cureus.47240. eCollection 2023 Oct. Cureus. 2023. PMID: 38021965 Free PMC article.
-
The Role of Endocrine Disruptors in Childhood Obesity: Unraveling the Obesogens.Horm Res Paediatr. 2025 Mar 26:1-14. doi: 10.1159/000545043. Online ahead of print. Horm Res Paediatr. 2025. PMID: 40139165 Review.
Cited by
-
Liver and Pancreatic Toxicity of Endocrine-Disruptive Chemicals: Focus on Mitochondrial Dysfunction and Oxidative Stress.Int J Mol Sci. 2024 Jul 6;25(13):7420. doi: 10.3390/ijms25137420. Int J Mol Sci. 2024. PMID: 39000526 Free PMC article. Review.
-
Ultra-Processed Foods and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): What Is the Evidence So Far?Nutrients. 2025 Jun 24;17(13):2098. doi: 10.3390/nu17132098. Nutrients. 2025. PMID: 40647203 Free PMC article. Review.
-
Adipose tissue as target of environmental toxicants: focus on mitochondrial dysfunction and oxidative inflammation in metabolic dysfunction-associated steatotic liver disease.Mol Cell Biochem. 2025 May;480(5):2863-2879. doi: 10.1007/s11010-024-05165-z. Epub 2024 Dec 20. Mol Cell Biochem. 2025. PMID: 39704874 Free PMC article. Review.
-
Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: primary and secondary gene responses with links to disease progression.Toxicol Sci. 2024 Aug 1;200(2):324-345. doi: 10.1093/toxsci/kfae057. Toxicol Sci. 2024. PMID: 38710495 Free PMC article.
-
Prognostic Impact of Metabolic Syndrome and Steatotic Liver Disease in Hepatocellular Carcinoma Using Machine Learning Techniques.Metabolites. 2024 May 27;14(6):305. doi: 10.3390/metabo14060305. Metabolites. 2024. PMID: 38921441 Free PMC article.
References
-
- Swinburn B.A., Kraak V.I., Allender S., Atkins V.J., Baker P.I., Bogard J.R., Brinsden H., Calvillo A., De Schutter O., Devarajan R., et al. The global syndemia of obesity, undernutrition and climate change: The report of the Lancet Commission. Lancet. 2019;393:791–846. doi: 10.1016/S0140-6736(18)32822-8. - DOI - PubMed
-
- Lamb J.C., Boffetta P., Foster W.G., Goodman J.E., Hentz K.L., Rhomberg L.R., Staveley J., Swaen G., Van Der Kraak G., Williams A.L. Critical comments on the state of the science of endocrine disrupting chemicals by WHO and UNEP—2012. Regul. Toxicol. Pharmacol. 2012;69:22–40. doi: 10.1016/j.yrtph.2014.02.002. - DOI - PubMed
-
- Gupta R., Kumar P., Fahmi N., Garg B., Dutta S., Sachar S., Matharu A.S., Vimaleswaran K.S. Endocrine Disruption and Obesity: A Current Review on the Obesogenic Environment. Curr. Res. Green Sustain. Chem. 2020;3:100009. doi: 10.1016/j.crgsc.2020.06.002. - DOI
-
- European Chemical Agency (ECHA) and European Food Safety Authority (EFSA) with the technical support of the Joint Research Centre (JRC) Andersson N., Arena M., Auteri D., Barmaz S., Grignard E., Kienzler A., Lepper P., Lostia A.M., Munn S., et al. Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009. EFSA J. 2018;16:e05311. doi: 10.2903/j.efsa.2018.5311. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources